In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-12 of 12 for your search:

Drug:  palonosetron hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-00055-18, NCT00415103

Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)(COMPLETED)

Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04594, NCT00687011

Phase III Randomized Study of APF530 Versus Palonosetron Hydrochloride in Combination With Dexamethasone For Prophylaxis of Acute- and Delayed-Onset, Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Undergoing Moderately or Highly Emetogenic Chemotherapy

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: APP-C2006-01, NCT00343460

Granisetron, Dexamethasone, Prochlorperazine, Aprepitant, and Palonosetron in Preventing Nausea in Patients Undergoing Chemotherapy for Breast Cancer

Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000544841, U10CA037420, URCC-04-02, URCC-U1105, U1105, NCT00475085

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2005-0506, NCT00412425

Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Platinum Chemotherapy

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: PAL/SC-IV-2008, 2008-002853-19, NCT01046240

Multi-day Doses in Prevention of Nausea and Emesis

Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 10862, KUMC-10862, MGI-KUMC-10862, NCT00631930, NCT00600353

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 6862, NCI-2009-01669, UWCC-6862, IR-6862, NCT00895245

Phase II Randomized Pilot Study of Palonosetron Hydrochloride in Preventing Radiotherapy-Induced Nausea and Vomiting in Patients With Primary Gastrointestinal and/or Retroperitoneal Sarcomas

Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N08C2, N08C2, NCT00903396

10.

Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting

Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000503649, OHSU-SOL-06006-LM, OHSU-IRB-2302, 2302, NCT00381862

11.

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Phase: No phase specified
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6140, NCI-2010-00801, UWCC-6140, UWCC-UW-6140, UWCC-05-9579-H/D, FHCRC-6140, MGI-FHCRC-6140, NCT00343863

12.

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)